Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

19 Mar 2026 bởi

In adolescents with well-controlled HIV, switching from an oral antiretroviral therapy (ART) regimen to the long-acting injectable cabotegravir plus rilpivirine combination appears to be not only safe and efficacious in maintaining viral suppression but also strongly favoured, according to the end-of-study data from the phase I/II IMPAACT 2017 study.

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

19 Mar 2026

Alternate-day fasting lessens oxygen use, enhances MFR in overweight individuals

19 Mar 2026

An alternate-day fasting (ADF) regimen for 3 weeks results in lower blood pressure and myocardial oxygen consumption (MVO2) and improves myocardial blood flow and flow reserve (MFR), reports a recent study.

Alternate-day fasting lessens oxygen use, enhances MFR in overweight individuals

19 Mar 2026

AI-assisted app shows promise in managing anorexia nervosa

19 Mar 2026 bởi

An artificial intelligence (AI)-assisted dietary recording application (app) demonstrates its potential as an alternative to expert evaluation for nutritional management in young patients with anorexia nervosa (AN), according to a study.

AI-assisted app shows promise in managing anorexia nervosa

19 Mar 2026

Use of rhGM-CSF promotes wound healing via macrophage immunomodulation

19 Mar 2026

Topical administration of recombinant human granulocyte macrophage–colony stimulating factor (rhGM-CSF) helps induce healing of diabetic and nondiabetic wounds, suggests a study.

Use of rhGM-CSF promotes wound healing via macrophage immunomodulation

19 Mar 2026

Phase III PHILA final analysis: Pyrotinib + trastuzumab and docetaxel prolongs PFS & OS in HER2+ Tx-naïve mBC

19 Mar 2026 bởi

Extended analysis of the phase III PHILA trial confirms superiority of pyrotinib in combination with trastuzumab and docetaxel (TD) vs placebo in combination with TD in sustaining longer progression-free survival (PFS) and improving overall survival (OS) in treatment-naïve patients with HER2-positive (HER2+) metastatic breast cancer (mBC).

Phase III PHILA final analysis: Pyrotinib + trastuzumab and docetaxel prolongs PFS & OS in HER2+ Tx-naïve mBC

19 Mar 2026

OASIS in nulliparous and multiparous Asian women: When is episiotomy appropriate?

19 Mar 2026 bởi

A retrospective study from the Chinese University of Hong Kong (CUHK) finds episiotomy to be protective against obstetric anal sphincter injury (OASIS) among nulliparous Asian women with singleton normal vaginal or instrumental delivery as well as multiparous women undergoing instrumental delivery, but not multiparous women having normal vaginal delivery.

OASIS in nulliparous and multiparous Asian women: When is episiotomy appropriate?

19 Mar 2026

Medically supervised ketogenic diet shows trends of improved PFS & OS in pancreatic cancer patients on chemo

19 Mar 2026 bởi

A randomized phase II trial reports feasibility of and trends towards improved progression-free survival (PFS) and overall survival (OS) with medically supervised ketogenic diet (MSKD) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (PDAC) receiving gemcitabine, nab‐paclitaxel and cisplatin chemotherapy.

Medically supervised ketogenic diet shows trends of improved PFS & OS in pancreatic cancer patients on chemo

19 Mar 2026

Sivelestat helps mitigate ARDS risk in cardiovascular procedures

19 Mar 2026

Treatment with sivelestat in patients undergoing cardiovascular procedures appears to lower the incidence of acute respiratory distress syndrome (ARDS) and all-cause mortality, as reported in a study.

Sivelestat helps mitigate ARDS risk in cardiovascular procedures

19 Mar 2026

Original New Drug Application Approvals by US FDA (16-28 February 2026)

19 Mar 2026

New drug applications approved by US FDA as of 16-28 February 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-28 February 2026)

19 Mar 2026

Original New Drug Application Approvals by US FDA (1-15 March 2026)

19 Mar 2026

New drug applications approved by US FDA as of 1-15 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 March 2026)

19 Mar 2026

Tin tức & Cập nhật

Xem bài viết Đa khoa

Xem

Chuyên ngành:

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

Alternate-day fasting lessens oxygen use, enhances MFR in overweight individuals

Alternate-day fasting lessens oxygen use, enhances MFR in overweight individuals

AI-assisted app shows promise in managing anorexia nervosa

AI-assisted app shows promise in managing anorexia nervosa

Use of rhGM-CSF promotes wound healing via macrophage immunomodulation

Use of rhGM-CSF promotes wound healing via macrophage immunomodulation

Phase III PHILA final analysis: Pyrotinib + trastuzumab and docetaxel prolongs PFS & OS in HER2+ Tx-naïve mBC

Phase III PHILA final analysis: Pyrotinib + trastuzumab and docetaxel prolongs PFS & OS in HER2+ Tx-naïve mBC

OASIS in nulliparous and multiparous Asian women: When is episiotomy appropriate?

OASIS in nulliparous and multiparous Asian women: When is episiotomy appropriate?

Medically supervised ketogenic diet shows trends of improved PFS & OS in pancreatic cancer patients on chemo

Medically supervised ketogenic diet shows trends of improved PFS & OS in pancreatic cancer patients on chemo

Sivelestat helps mitigate ARDS risk in cardiovascular procedures

Sivelestat helps mitigate ARDS risk in cardiovascular procedures

Original New Drug Application Approvals by US FDA (16-28 February 2026)

Original New Drug Application Approvals by US FDA (16-28 February 2026)

Original New Drug Application Approvals by US FDA (1-15 March 2026)

Original New Drug Application Approvals by US FDA (1-15 March 2026)